Press coverage about Kamada (NASDAQ:KMDA) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a news impact score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.7302868241876 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
KMDA has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Jefferies Group reissued a “buy” rating and set a $7.00 price objective on shares of Kamada in a research report on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $8.50.
Shares of Kamada (NASDAQ KMDA) traded up $0.03 during mid-day trading on Monday, hitting $4.70. 5,200 shares of the stock were exchanged, compared to its average volume of 69,882. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a quick ratio of 2.73, a current ratio of 3.71 and a debt-to-equity ratio of 0.02.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/04/kamada-kmda-receiving-somewhat-favorable-media-coverage-analysis-shows.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.